Viacell News (NASDAQ:VIAC)
| Latest Viacell News Headlines | | Date | Time | Source | | | 05/22/2007 | 11:57AM | PRNUS | BullMarket.com Updates Outlooks on Stem Cell Companies
PRINCETON, N.J., May 22 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com/), an online investment newsletter focused on long- term growth and income-generating stocks, announced today that it has provided subscribers with a detailed report updating outlooks on stem cell companies including Geron (NASDAQ:GERN... More...>> |
| 03/22/2007 | 6:05PM | PRNUS | VIDEO from Medialink and ViaCell: Study Looking to Extend Fertility in Women Begins
NEW YORK, March 22 /PRNewswire/ -- A growing number of women are now having their first babies well into their thirties -- and even in their forties. There are several reasons for waiting to start a family. Women who wait usually have more financial security, more emotional maturity and more time to commit to their... More...>> |
| 09/18/2006 | 9:30AM | PRNUS | ViaCell to Present at the UBS 2006 Global Life Sciences Conference
CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that Marc D. Beer, President and Chief Executive Officer of ViaCell, will present an update on its product pipeline and business activities at the UBS 2006 Global Life Sciences Conference on Monday, September 25, 2006 at... More...>> |
| 08/03/2006 | 7:30AM | PRNUS | ViaCell Reports Second Quarter 2006 Financial Results
CAMBRIDGE, Mass., Aug. 3 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced its consolidated financial results for the second quarter ended June 30, 2006.
Total revenues were $13.5 million for the second quarter of 2006 compared to $11.4 million for the same period in 2005. Sales of ViaCord(R... More...>> |
| 07/24/2006 | 8:30AM | PRNUS | ViaCell Announces Completion of CB001 Phase I Clinical Trial
CAMBRIDGE, Mass., July 24 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up. CB001 is an investigational therapy being studied as a potential therapeutic option... More...>> |
| 07/20/2006 | 8:30AM | PRNUS | ViaCell to Report Second Quarter 2006 Financial Results on August 3, 2006
CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) will announce its second quarter 2006 financial results on August 3, 2006 before the opening of U.S. financial markets. In connection with this announcement, ViaCell will host a conference call and live audio webcast on August 3, 2006 at... More...>> |
| 06/26/2006 | 7:32AM | PRNUS | ViaCell Finalizes IDE and Announces Plans to Commence Clinical Trial of ViaCyte in Oocyte Cryopreservation
CAMBRIDGE, Mass., June 26 /PRNewswire-FirstCall/ -- . ViaCell, Inc. (NASDAQ:VIAC) announced today the United States Food and Drug Administration (FDA) has conditionally approved its Investigational Device Exemption (IDE) to evaluate its ViaCyte(SM) investigational product offering for the cryopreservation and thawing... More...>> |
| 06/13/2006 | 2:00AM | PRNUS | ViaCell Announces Cardiac Collaboration with Centocor Research and Development, Inc.
CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) announced today the signing of a cardiac collaboration agreement with the Stem Cell Internal Venture (SCIV) of Centocor Research and Development, Inc. to evaluate ViaCell's proprietary cord blood-derived multi-potent stem cells as a potential... More...>> |
| 06/07/2006 | 8:30AM | PRNUS | ViaCell to Present at the 2006 Pacific Growth Equities' Life Sciences Growth Conference
CAMBRIDGE, Mass., June 7 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that Jim Corbett, President of ViaCell Reproductive Health, will present an update on its product pipeline and business activities at the 2006 Pacific Growth Equities Life Sciences Growth Conference on Wednesday, June 14... More...>> |
| 05/30/2006 | 8:30AM | PRNUS | ViaCell Announces New Office Actions Rejecting PharmaStem Patent Claims
CAMBRIDGE, Mass., May 30 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that, following a re-examination, the United States Patent and Trademark Office (PTO) issued two new office actions rejecting all of the claims of PharmaStem Therapeutics Inc.'s U.S. Patent No. 5,192,553 and U.S. Patent No... More...>> |
| 05/30/2006 | 8:00AM | PRNUS | ViaCell and Children's Hospital Oakland Research Institute Expand Sibling Cord Blood Donor Program
CAMBRIDGE, Mass., May 30 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) and Children's Hospital Oakland Research Institute (CHORI) today announced an agreement to combine their efforts in the area of directed transplants of sibling donor cord blood. The combined program brings together CHORI's nation-wide program... More...>> |
| 05/05/2006 | 12:00PM | PRNUS | New Data Highlights Importance of Umbilical Cord Blood for Transplantation
BERLIN, May 5 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today presented data at the 12th Annual Meeting of the International Society for Cellular Therapy (ISCT) supporting the importance of family banked umbilical cord blood, a non-controversial source of stem cells with proven clinical utility in treating... More...>> |
| 05/02/2006 | 7:30AM | PRNUS | ViaCell Reports First Quarter 2006 Financial Results
CAMBRIDGE, Mass., May 2 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced its consolidated financial results for the three months ended March 31, 2006.
Total revenues in the first quarter of 2006 were $12.1 million compared to total revenues of $10.1 million for the same period in 2005. Sales of... More...>> |
| 05/01/2006 | 11:43AM | PRNUS | U.S. Patent Office Issues Office Actions Rejecting All Claims in Two PharmaStem Umbilical Cord Blood Patents
CAMBRIDGE, Mass., May 1 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that, following a re-examination, the United States Patent and Trademark Office (PTO) has issued office actions rejecting all of the claims of PharmaStem Therapeutics Inc.'s U.S. Patent Nos. 6,461,645 and 5,004,681. These... More...>> |
| 04/26/2006 | 8:30AM | PRNUS | ViaCell to Present at the Deutsche Bank 31st Annual Health Care Conference
CAMBRIDGE, Mass., April 26 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that Marc D. Beer, President and Chief Executive Officer of ViaCell, will present an update on its product pipeline and business activities at the Deutsche Bank 31st Annual Health Care Conference on Wednesday, May 3, 2006... More...>> |
| 04/25/2006 | 9:00AM | PRNUS | First FDA Clearance of Sterile Field Cord Blood Collection Bag ViaCell and Pall Announce Collaborative Agreement
EAST HILLS, N.Y. and CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) and Pall Corporation (NYSE:PLL) announced today the first U.S. Food and Drug Administration clearance of a cord blood collection bag suitable for use in a sterile field. Pall and ViaCell collaborated on the development... More...>> |
| 04/18/2006 | 8:30AM | PRNUS | ViaCell to Report First Quarter 2006 Financial Results on May 2, 2006
CAMBRIDGE, Mass., April 18 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) will announce its first quarter 2006 financial results on May 2, 2006 before the opening of U.S. financial markets. In connection with this announcement, ViaCell will host a conference call and live audio webcast on May 2, 2006 at 10:00... More...>> |
| 04/10/2006 | 9:00AM | PRNUS | ViaCell Announces Executive Appointments in its Reproductive Health Business
James Corbett Named President of ViaCell Reproductive Health
CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) today announced that Mr. James Corbett has joined the Company in the newly created position, President of ViaCell Reproductive Health. In this position, Mr. Corbett will have... More...>> |
| 03/13/2006 | 11:45AM | PRNUS | ViaCell Reports Encouraging Preclinical Findings of Unrestricted Somatic Stem Cells from Cord Blood
ATLANTA, March 13 /PRNewswire-FirstCall/ -- ViaCell, Inc. (NASDAQ:VIAC) announced today preclinical findings evaluating Unrestricted Somatic Stem Cells (USSCs), pluripotent stem cells cultivated from human cord blood, in a small animal model of myocardial infarction. In the study USSCs showed a dose-dependent response... More...>> |
| 03/07/2006 | 8:00AM | PRNUS | The Bull Market Report Publishes In-Depth Report on Stem Cell Companies
PRINCETON, N.J., March 7 /PRNewswire/ -- The Bull Market Report (http://www.bullmarket.com/), an online investment newsletter focused on long- term growth and income-generating stocks, announced that it has published an in-depth report on biotech companies focused on stem cell research, including Geron (NASDAQ:GERN... More...>> |
|
|
|